| Version 2.1.1.0 |
|
|
Abstract
Grant Number: 2R44CA086653-02A1 PI Name: CATTANEO, MAURIZIO V. PI Email: mcattaneo@ivreapharma.com PI Title: Project Title: Topical Retinoids for Chemoprevention of Melanoma Abstract: DESCRIPTION (provided by applicant): Malignant melanoma's incidence is increasing by 2.7% annually even as most other cancers are experiencing a decline in incidence. The long-term objective of this project is to commercialize a topical formulation containing retinoic acid (ATRA) for subjects with dysplastic nevi at a higher risk of developing malignant melanoma. However, ATRA is highly irritating to the skin. Several topical delivery systems have been shown to reduce ATRA-induced skin irritation. Phase I studies have shown that the biopolymer chitosan acts as a topical delivery system for ATRA. In this Phase II SBIR study we propose to: (1) standardize the topical formulation containing the ATRA/chitosan delivery system according to our IND 60,073, (2) test the long-term toxicity and irritation of the formulation in both rodents and non-rodents species according to FDA 21 CFR, Part 58, (3) determine whether 6 months of topical ATRA/chitosan will result in a significant clinical improvement of dysplastic nevi, and/or a decrease in the dysplasia grade, and/or a change in the expression of proliferation biomarkers, by performing a multicenter controlled clinical trial involving 16 dysplastic nevi subjects using Internet-based randomization, electronic data capture, coordination and monitoring, and pre and post study clinical and histological assessment.
Thesaurus Terms:
chemoprevention, drug design /synthesis /production, melanoma, retinoate, retinoid, topical drug application
biomarker, biotherapeutic agent, dosage, drug delivery system, polymer, skin disorder chemotherapy, skin pharmacology
biopsy, clinical research, histopathology, human subject, immunocytochemistry, laboratory rabbit, laboratory rat
Institution: IVREA, INC. 216 RICCIUTI DR QUINCY, MA 02169 Fiscal Year: 2003 Department: Project Start: 01-JUN-2000 Project End: 31-MAR-2005 ICD: NATIONAL CANCER INSTITUTE IRG: ZRG1